2018-08-29T15:32:33-05:00 2017-12-31 221430039 SOBEL & CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2017-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR 2125886624 2018-08-29 1 BRIDGET HARTNETT P01429163 9739949494 2018-08-23 2017 2022-09-23 18:48:47Z SCOTT KENNEDY 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 2165092 0 X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY SOLVING KIDS' CANCER FINDS, FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO CURE CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS. 7 6 6 17 0 0 903826 1715498 0 0 4821 4719 259838 272647 1168485 1992864 456965 1032334 0 0 457770 397833 0 0 125535 298611 334133 1213346 1764300 -44861 228564 2479739 2712789 12695 17181 2467044 2695608 X SKC IMPACTS CHILDREN IN THE SHORT-TERM THROUGH THE INITIATION OF CLINICAL RESEARCH TRIALS OF INVESTIGATIONAL TREATMENT STRATEGIES. OUR VISION IS TO CONTINUE EXPANDING THE ARMAMENTARIUM OF EFFECTIVE AND LESS TOXIC TREATMENT STRATEGIES FOR PEDIATRIC ONCOLOGISTS TO UTILIZE UNTIL LONG-TERM SURVIVAL IS A REALITY FOR ALL CHILDREN WITH HIGH-RISK SOLID TUMORS AND BRAIN TUMORS. SOLVING KIDS' CANCER FINDS, FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO CURE CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS. 0 0 1392025 1032334 SKC ACTIVELY PURSUES THE UNDERSTANDING OF THE RESEARCH LANDSCAPE FOR NEUROBLASTOMA, HIGH-RISK BRAIN TUMORS AND SARCOMAS AND DEVELOPS CLINICAL RESEARCH PROGRAMS TO ADDRESS THE CURRENT UNMET NEEDS OF CHILDREN CURRENTLY AFFECTED BY THESE DISEASES AND CHILDREN YET TO BEDIAGNOSED. SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS WHILE DECADES-OLD MODALITIES LIKE CHEMOTHERAPY AND RADIATION REMAIN THE STANDARDS-OF-ART. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE,NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, NOVEL/SYNERGISTIC COMBINATION TREATMENTS, NEW TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL THERAPY DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARESKC HAS HELPED TO DEVELOP 24 CLINICAL TRIALS FOR CHILDREN RESULTING IN 23 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS. IN 2017, SKC HELPED PRIORITIZE, DEVELOP AND GRANT SUPPORT SEVERAL IMPORTANT MISSION PROGRAMS INCLUDING: A PH I CLINICAL TRIAL INVESTIGATION A TRIPLET COMBINATION REGIMEN OF ANTI-GD2 ANTIBODY (LONG-TERM INFUSION) + ANTI-PD1 CHECKPOINT INHIBITOR + MIBG TARGETED RADIOTHERAPY FOR HIGH-RISK NEUROBLASTOMA IN A 3-COUNTRY TRANSATLANTIC TRIAL; A PH I CLINICAL TRIAL INVESTIGATING APX-005M (A CD40 AGONIST) IMMUNOTHERAPY IN CHILDREN WITH HIGH-RISK BRAIN TUMORS; A FIRST EFFORT TO CHARACTERIZE ETMR BRAIN TUMORS THROUGH SINGLE-CELL RNA SEQUENCING. THIS MULTIYEAR PROGRAM WILL DEFINE THE CELLULAR ARCHITECTURE OF ETMR TUMORS THROUGH SEVERAL PATIENT SAMPLES IN A MULTI-COUNTRY COLLABORATIVE EFFORT. 1392025 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 0 1 6 1 0 0 0 0 0 1 1 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THE ORGANIZATION 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 JOHN LONDON CHAIRMAN, CO-FOUNDER 2.00 X X 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 40.00 X X 148398 0 15189 KHALIL BARRAGE DIRECTOR 2.00 X 0 0 0 CATHERINE LONDON CO-FOUNDER, DIRECTOR 2.00 X 0 0 0 CHANNING STAVE SECRETARY 2.00 X X 0 0 0 MARK SAVOYE TREASURER 2.00 X 0 0 0 MICHAEL NIEDZIELSKI DIRECTOR 2.00 X 0 0 0 148398 0 15189 1 0 1 0 0 325055 1390443 1715498 4719 4719 444875 325055 172228 272647 272647 1992864 0 0 277366 1032334 1032334 163587 163587 171884 33835 47312 90737 30603 9718 3394 17491 31759 12547 10296 8916 30811 30811 152704 111216 41488 10315 5538 4777 8428 8428 48364 48364 10855 9860 836 159 3212 3117 95 33324 33324 5133 5133 DONATIONS 15000 15000 MISCELLANEOUS 6961 6359 602 DUES AND SUBSCRIPTIONS 2909 2909 PRINTING AND SHIPPING 2764 2764 3353 811 2453 89 1764300 1392025 246740 125535 226474 405761 2181077 2234550 10720 36720 24064 26777 226252 220856 33819 5396 3585 3585 2479739 2712789 12695 17181 12695 17181 X 1680427 1599877 786617 1095731 2467044 2695608 2479739 2712789 228564 0 X X 0 1 X 1 0 X 309184 1381381 761768 1198351 1715498 5366182 309184 1381381 761768 1198351 1715498 5366182 222250 5143932 7027 5638 5202 4821 4719 27407 5393589 0.95370 0.93190 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5160 5160 0 221092 215696 5396 5396 X 1992864 0 1992864 0 1992864 1764300 0 1764300 0 1764300 PART X, LINE 2: THE ORGANIZATION FOLLOWS STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DERECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ON UNRECOGNIZED TAX BENEFITS IN INCOME TAX EXPENSE. NO INTEREST AND PENALTIES WERE RECORDED DURING 2017 AND 2016. AT DECEMBER 31, 2017 AND 2016, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES. SPRING CELEBRATION 769930 325055 444875 92504 16520 63204 769930 325055 444875 92504 16520 63204 172228 272647 1 BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 333334 CASH CANCER RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 633 THIRD AVENUE 28TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 120000 CASH CANCER RESEARCH DUKE UNIVERSITY BOX 104008 DURHAM NC 27705 560532129 501(C)(3) 74000 CASH CANCER RESEARCH CHILDREN'S HOSPITAL OF PHILADELPHIA 3615 CIVIC CENTER BLVD 142-B PHILADELPHIA PA 191044318 231352166 501(C)(3) 210000 CASH CANCER RESEARCH CHILDREN'S HOSPITAL OF LOS ANGELES 4650 SUNSET BLVD LOS ANGELES CA 90027 951690977 501(C)(3) 250000 CASH CANCER RESEARCH UNIVERSITY OF CALIFORNIA SANFRANCSICOREGENTS 1111 FRANKLIN STREET OAKLAND CA 94607 946036493 501(C)(3) 45000 CASH CANCER RESEARCH 6 PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. X X X 0 0 0 0 0 0 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 148398 0 0 0 0 0 0 0 15189 0 163587 0 0 0 PART I, LINE 3 FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS FORM 990, PART VI, SECTION A, LINE 2 JOHN LONDON AND CATHERINE LONDON ARE MARRIED. FORM 990, PART VI, SECTION B, LINE 11B THE COMPLETED FORM 990 IS SENT TO THE BOARD OF DIRECTORS PRIOR TO FILING FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALLY AT THE BOARD MEETING. ALL STAFF AND BOARD MEMBERS ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY STATEMENT ON AN ANNUAL BASIS. ANY CONFLICTS THAT ARISE DURING THE COURSE OF THE YEAR ARE REQUIRED TO BE DISCLOSED AND RESOLVED BEFORE THE TRANSACTION IS COMPLETED. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED BY CONDUCTING A FAIR MARKET VALUE COMPARISON OF OTHER ORGANIZATIONS BY THE BOARD CHAIR. FACTORS INCLUDE THE NUMBER OF HOURS WORKED AND THE BREADTH OF ROLES AND RESPONSIBILITIES. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION'S FORM 990 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS IS MADE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: THE BOARD OF DIRECTORS IS CHARGED WITH OVERSIGHT IN REGARDS TO REVIEW OF THE FINANCIALS AND SELECTION OF THE AUDITOR. FORM 990, PART III, LINE I (CONTINUATION): SKC FULFILLS THIS MISSION BY: 1. MAINTAINING A COMPREHENSIVE UNDERSTANDING OF THE GLOBAL CHILDHOOD CANCER RESEARCH LANDSCAPE TO EFFECTIVELY/RESPONSIBLY ADVANCE THE HIGHEST-IMPACT CLINICAL RESEARCH. 2. REMAINING INDEPENDENT OF ANY INSTITUTION, CANCER CENTER, OR RESEARCHER TO OBJECTIVELY SUPPORT THE BEST RESEARCH PROJECTS 3. SERVING AS A RESEARCH ADVOCATE TO ENSURE THAT RESEARCH IS CHILD-FOCUSED, ACCESSIBLE AND IS STRUCTURED TO HAVE POSITIVE IMPACT ON CHILDREN IN TREATMENT TODAY AS WELL AS IN THE FUTURE. 4. PARTNERING WITH LIKE-MINDED ORGANIZATIONS TO FUEL THE DEVELOPMENT OF NEW TREATMENTS WITH A COLLECTIVE VOICE AND POOL OF FUNDING 5. SHARING OUR KNOWLEDGE WITH FAMILIES IN TREATMENT AND ACTING AS GLOBAL ADVOCATES ON BEHALF OF THE CHILDREN TO ENSURE THEIR UNMET NEEDS ARE BEING ADDRESSED.